

## **CCR Group B.V. reinforces its position in (bio)pharmaceutical and bioanalytical testing with the acquisition of Accelerero Bioanalytics GmbH**

Berlin, 31 May 2022

Accelerero Bioanalytics GmbH (“Accelerero”) announces the acquisition by the CCR Group B.V. Amsterdam, an integrated Contract Research Organization active in testing for the pharmaceutical, (agro)chemical and biotech industry.

Accelerero is a GLP and GCP qualified laboratory, with a strong focus on providing services in regulatory non-clinical and clinical development of Advanced Therapy Medicinal Products (ATMP) and biologics. The company is also active in biosafety testing and biological R&D. The acquisition strengthens the geographical footprint and reinforces CCR’s platform to further accelerate the deployment of desired testing methodologies to support the pharmaceutical and biotech industries across the entire drug development cycle.

“On behalf of all Accelerero employees I am happy to join the CCR family as a new integral part. Accelerero complements CCR’s activities with its non-clinical and clinical expertise for their international clients. This partnership will enable CCR’s clients to benefit from a broader service portfolio and will promote Accelerero to the next level of expansion. The entire Accelerero team is very much looking forward to adding value to CCR’s customers,” said Christian Lange, MD of Accelerero.

CEO of CCR, Dr. Marleen van Nuenen adds: “With the acquisition of Accelerero Bioanalytics, CCR is expanding its portfolio in the GLP and GCP testing area for biopharmaceutical companies. This acquisition is in line with our growth strategy and vision to serve high-demanding customers in different stages of the development of their (biological)drugs. We look forward to strengthening Accelerero’s testing portfolio and operating footprint by providing access to the full range of services, capabilities, and knowledge of CCR.”

### **About Accelerero**

Accelerero is a certified GLP test facility and operates in compliance with ICH GCP regulations. Accelerero offers services for research areas like Nucleic Acid-based therapeutics and Advanced Therapy Medicinal Products (ATMP) like genetically modified virus-based gene therapy vectors. The assay portfolio includes qPCR, immunogenicity testing, flow cytometry, and ELISA. Accelerero serves biopharmaceutical companies all over the world.

### **About CCR**

CCR is a Contract Research Organization with multiple laboratory sites in Germany and the Netherlands offering a comprehensive spectrum of integrated services to the pharmaceutical, (agro)chemical and biotech industry. CCR serves customers all over the world spanning across Europe, Asia and the US. The overall portfolio of competencies is consistent with the global needs in (bio)pharmaceutical and (agro)chemical testing services.

For additional information on Accelerero's services, please feel free to use our website contact form, or send us an email to [service\(at\)accelero-bioanalytics.com](mailto:service(at)accelero-bioanalytics.com). The Accelerero team will be happy to assist you.

Accelerero Bioanalytics GmbH  
Center for Biotechnology and Environment  
Volmerstrasse 9A  
12489 Berlin  
GERMANY

Primary Contact:  
Christian Lange, Managing Director  
Telephone +49 30 610 910 300

qPCR  
Biodistribution  
ELISA  
EliSpot / FluoroSpot  
Flow cytometry  
Multiplex immunoassays  
Multiplex miRNA assays  
Cell culture  
Microbiology  
GLP trainings & seminars

Follow us on



Read [binding-assay.com](http://binding-assay.com) for blog and case studies.

Curious about the other CCR Group family members?

